Suppr超能文献

有明显骨髓转移的乳腺癌患者的预后评估

Prognostic evaluation of breast cancer patients with evident bone marrow metastasis.

作者信息

Demir Lutfiye, Akyol Murat, Bener Sadi, Payzin Kadriye Bahriye, Erten Cigdem, Somali Isil, Can Alper, Dirican Ahmet, Bayoglu Vedat, Kucukzeybek Yuksel, Alacacioglu Ahmet, Calli Aylin Orgen, Tarhan Mustafa Oktay

机构信息

Department of Medical Oncology, Ataturk Training and Research Hospital, Katip Celebi University, Izmir, Turkey; Department of Basic Oncology, Institute of Oncology, Dokuz Eylul University, Izmir, Turkey.

出版信息

Breast J. 2014 May-Jun;20(3):279-87. doi: 10.1111/tbj.12264. Epub 2014 Mar 27.

Abstract

In this study, we aimed to evaluate the clinicopathologic characteristics and prognosis of breast cancer (BC) patients with symptomatic bone marrow metastasis (BMM). Fifty-four BC patients, including patients with and without BMM, were evaluated retrospectively. In particular, the clinicopathologic features and survival of the patients with BMM (n = 27) were assessed and compared with the patients without BMM. All of the patients with BMM also had osseous metastases, and bone was the first site for distant recurrence in the majority of patients in the study group. Anemia was the most frequent symptom at presentation. The median time to BMM was 36.1 months (range 1.6-70.5 months, 95% CI). HER2(+) patients developed BMM earlier than HER2(-) patients (3.2 versus 38.3 months, 95% CI; p = 0.05). Patients with advanced disease at the time of initial BC diagnosis developed BMM earlier than patients with early disease (p = 0.04). Time to development of BMM was significantly shorter in tumors with perinodal infiltration (p = 0.001) and multicentric focus (p = 0.025). Median survival time after the diagnosis of apparent BMM was 6.43 months. Survival after BMM diagnosis in patients with grade III tumors was significantly shorter than in patients with grade I-II tumors (1.43 versus 5.36 months, 95% CI; p < 0.001). Systemic therapy after BMM diagnosis significantly prolonged survival (17.3 versus 0.93 months, 95% CI; p < 0.001). Hormone receptor-positive, high-grade, advanced-stage tumors at the time of initial BC diagnosis were more common in patients with BMM. Invasive lobular histology was also more frequent in patients with BMM. In conclusion, the presence of hormone receptor-positive, multicentric, grade III, advanced-stage tumors may be important risk factors for the development of evident BMM in BC patients. Systemic single-agent chemotherapy can prolong survival in these patients. However, multicenter analyses are required to verify these findings.

摘要

在本研究中,我们旨在评估有症状骨髓转移(BMM)的乳腺癌(BC)患者的临床病理特征及预后。对54例BC患者进行回顾性评估,其中包括有和没有BMM的患者。特别对27例有BMM患者的临床病理特征及生存情况进行评估,并与无BMM患者进行比较。所有有BMM的患者均有骨转移,且在研究组大多数患者中,骨是远处复发的首发部位。贫血是最常见的就诊症状。发生BMM的中位时间为36.1个月(范围1.6 - 70.5个月,95%CI)。HER2(+)患者发生BMM的时间早于HER2(-)患者(3.2个月对38.3个月,95%CI;p = 0.05)。初始BC诊断时处于晚期疾病的患者发生BMM的时间早于早期疾病患者(p = 0.04)。有淋巴结周围浸润(p = 0.001)和多中心病灶(p = 0.025)的肿瘤发生BMM的时间显著缩短。明显BMM诊断后的中位生存时间为6.43个月。III级肿瘤患者BMM诊断后的生存时间显著短于I-II级肿瘤患者(1.43个月对5.36个月,95%CI;p < 0.001)。BMM诊断后的全身治疗显著延长了生存时间(17.3个月对0.93个月,95%CI;p < 0.001)。初始BC诊断时激素受体阳性且为高级别、晚期肿瘤在有BMM的患者中更常见。浸润性小叶组织学在有BMM的患者中也更常见。总之,激素受体阳性、多中心、III级、晚期肿瘤的存在可能是BC患者发生明显BMM的重要危险因素。全身单药化疗可延长这些患者的生存时间。然而,需要多中心分析来验证这些发现。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验